Last update July 11, 2016

Линкомицин

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

A Lincosamide type antibacterial drug which is structurally similar to clindamycin.

As clindamycin, it is excreted in breast milk in clinically non-significant amount with no problems being reported in infants whose mothers were treated with it.

Its low oral bioavailability that further decreases with simultaneous ingestion of food, hinders the drug passage to the infant plasma from ingested mother’s milk , except in preterm babies and immediate neonatal period, in which they may occur an increased intestinal permeability.

Among infants whose mothers are treated with antibiotics, an alteration of the intestinal flora may appear. In case of infant's fever, the possibility of false negative results of bacterial cultures should be taken into account.

Alternatives

We do not have alternatives for Линкомицин since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Линкомицин is Lincomycin in Cyrillic.

Is written in other languages:

Линкомицин is also known as

Group

Линкомицин belongs to this group or family:

Tradenames

Main tradenames from several countries containing Линкомицин in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 20 - 35 %
Molecular weight 407 daltons
Protein Binding 72 %
Tmax 2 - 4 hours
T½ 5 hours
M/P ratio 0.2 - 0.9 -
Theoretical Dose 0.19 mg/Kg/d
Relative Dose 0. 6 - 0. 8 %
Ped.Relat.Dose 1 - 2 %

References

  1. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Sep;40(9):684-90. Review. Abstract Full text (link to original source) Full text (in our servers)
  2. Stéen B, Rane A. Clindamycin passage into human milk. Br J Clin Pharmacol. 1982 Abstract Full text (link to original source) Full text (in our servers)
  3. Wilson JT. Milk/plasma ratios and contraindicated drugs. In: Wilson JT, ed. Drugs in Breast Milk. Balgowlah, Australia: ADIS Press: 78–9. 1981
  4. MEDINA A, FISKE N, HJELT-HARVEY I, BROWN CD, PRIGOT A. ABSORPTION, DIFFUSION, AND EXCRETION OF A NEW ANTIBIOTIC, LINCOMYCIN. Antimicrob Agents Chemother (Bethesda). 1963 Abstract

Total visits

2,085

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM